NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

You indicated that safety was one of the big reasons Phase 3 trials failed and gave a percentage of failed trials. I pointed out that safety is not at all an issue with DCVax-L and therefore safety would not be a reason for DCVax-L to flunk and therefore the percentage chance of DCva-L failing must logically be significantly less than what you gave since only lack of efficacy (in the FDA’s eyes) or issues with the trial design (which do not effect the safety profile but only efficacy depending how tough the regulators choose to be) remain as risks.